Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fadraciclib in Leukemias or MDS
NCT05168904Phase 2Suspended
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fadraciclib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Cyclacel Pharmaceuticals, Inc.. Started Oct 2021; status: suspended.
02
Drugs
fadraciclib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05168904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168904.